Purple Biotech Ltd.
PPBT
Rank in Stocks
#34107
Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies... Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies for cancer patients in the United States, specifically addressing challenges like tumor immune evasion and drug resistance. Its diverse oncology pipeline includes CM24, a humanized monoclonal antibody that targets and blocks carcinoembryonic antigen related cell adhesion molecule 1 (CEACAM1). Currently in Phase 2 clinical trials, CM24 is being investigated as a combination therapy with anti-PD-1 checkpoint inhibitors for treating pancreatic ductal adenocarcinoma. Another candidate is NT219, a small molecule compound in Phase 1/2 clinical trials, which functions by inhibiting insulin receptor substrate 1 and 2 (IRS1/2) and signal transducer and activator of transcription (STAT). This compound is being developed for recurrent and/or metastatic squamous cell carcinoma of the head and neck, or colorectal adenocarcinoma. Furthermore, IM1240, a multi-valent antibody designed to activate an anti-tumoral immune response against 5T4-positive tumors, is in its preclinical stage. The company has established significant collaborations, including an agreement with Bristol Myers Squibb Company for Phase 2 clinical trials to assess CM24 in combination with the PD-1 inhibitor nivolumab and chemotherapy, as well as a partnership with Mor Research Applications. Formerly known as Kitov Pharma Ltd., the company adopted the name Purple Biotech Ltd. in December 2020 and is headquartered in Rehovot, Israel.
Share Price
$1.34
Last synced: 2026-11-09
Market Cap
$68.87K
Change (1 day)
2.29%
Change (1 year)
-83.86%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Purple Biotech Ltd. (PPBT)
Category
Healthcare
EPS for Purple Biotech Ltd. (PPBT)
EPS as of June 2026 TTM: $-2.22
According to Purple Biotech Ltd.'s latest financial reports, its current EPS (TTM) is $-2.22. At the end of 2025 the company had an EPS of $-5.50, a decrease compared to its 2024 EPS of $-4.42.
EPS history for Purple Biotech Ltd. from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.22 | -59.64% |
| 2025 | $-5.50 | 24.43% |
| 2024 | $-4.42 | -75.39% |
| 2023 | $-17.96 | -25.17% |
| 2022 | $-24.00 | 20.00% |
| 2021 | $-20.00 | -60.00% |
| 2020 | $-50.00 | -10.71% |
| 2019 | $-56.00 | -24.32% |
| 2018 | $-74.00 | -71.32% |
| 2017 | $-258.00 | -38.86% |
| 2016 | $-422.00 | -51.72% |
| 2015 | $-874.00 | -81.36% |
| 2014 | $-4.69K | -26.82% |
| 2013 | $-6.41K | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -805.41% |
US
|
|
| $-7.07 | 218.47% |
US
|
|
| $-5.29 | 138.29% |
AU
|
|
| $12.88 | -680.18% |
BE
|
|
| $21.56 | -1,071.17% |
NL
|
Questions about Purple Biotech Ltd.'s earnings per share (EPS)
What is Purple Biotech Ltd.'s earnings per share (EPS)?
Purple Biotech Ltd.'s earnings per share (EPS) over the last twelve months is $-2.22, as of Jun 2026.
What was Purple Biotech Ltd.'s earnings per share (EPS) in 2025?
In 2025, Purple Biotech Ltd.'s earnings per share (EPS) was $-5.50, compared with $-4.42 in 2024.
How has Purple Biotech Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Purple Biotech Ltd.'s earnings per share (EPS) was highest in 2024 ($-4.42) and lowest in 2020 ($-50.00).
How does Purple Biotech Ltd.'s earnings per share (EPS) compare with similar companies?
Purple Biotech Ltd.'s earnings per share (EPS) ($-2.22) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.